Semaglutide/Glycine 2.5 mg/7.5 mg /mL 4.5mL Vial

Semaglutide / Glycine 2.5 mg / 7.5 mg per mL – 4.5 mL Vial (Ships Cold) is a compounded injectable formulation combining semaglutide, a GLP-1 receptor agonist, with glycine, a non-essential amino acid. This combination is designed for research or investigational use in metabolic health, weight management, and glycemic regulation. Semaglutide 2.5 mg/mL – Semaglutide mimics endogenous GLP-1, enhancing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and promoting satiety. It is widely studied for type 2 diabetes and weight management. A 4.5 mL vial contains a total of 11.25 mg of semaglutide. Glycine 7.5 mg/mL – Glycine is an amino acid involved in protein synthesis, neurotransmission, and metabolic regulation. Research suggests glycine may improve insulin sensitivity, support hepatic function, and reduce oxidative stress. The 4.5 mL vial contains a total of 33.75 mg of glycine. The vial is shipped cold to maintain peptide stability and potency. The solution is intended for subcutaneous injection in controlled research or clinical settings. Proper dosing, storage, and administration under medical supervision are critical. Semaglutide efficacy and mechanism (GLP-1 agonist): https://pubmed.ncbi.nlm.nih.gov/32809483/ Glycine’s metabolic and insulin-sensitizing effects: https://pubmed.ncbi.nlm.nih.gov/24650304/